Selected article for: "expert opinion and infectious disease"
Author: Mahler, Michael; Meroni, Pier-Luigi; Infantino, Maria; Buhler, Katherine A.; Fritzler, Marvin J.
Title: Circulating Calprotectin as a Biomarker of COVID-19 Severity
  • Cord-id: duvz61ye
  • Document date: 2021_4_13
    • ID: duvz61ye
    Snippet: INTRODUCTION: Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Although demographic and clinical parameters such as sex, age, comorbidities, genetic background and various biomarkers have been identified as risk factors, there is an unmet need to predict the risk and onset of severe inflammatory disease leading to poor clinical outcomes. In addition, very few mechanistic biomarkers are available to info
    Document: INTRODUCTION: Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Although demographic and clinical parameters such as sex, age, comorbidities, genetic background and various biomarkers have been identified as risk factors, there is an unmet need to predict the risk and onset of severe inflammatory disease leading to poor clinical outcomes. In addition, very few mechanistic biomarkers are available to inform targeted treatment of severe (auto)-inflammatory conditions associated with COVID-19. Calprotectin, also known as S100A8/S100A9, MRP8/14 (Myeloid-Related Protein) or L1, is a heterodimer involved in neutrophil-related inflammatory processes. In COVID-19 patients, calprotectin levels were reported to be associated with poor clinical outcomes such as significantly reduced survival time, especially in patients with severe pulmonary disease. AREAS COVERED: Pubmed was searched using the following keywords: Calprotectin + COVID19, S100A8/A9 + COVID19, S100A8 + COVID-19, S100A9 + COVID-19, MRP8/14 + COVID19; L1 + COVID-19 between May 2020 and 8 March 2021. The results summarized in this review provide supporting evidence and propose future directions that define calprotectin as an important biomarker in COVID-19. EXPERT OPINION: Calprotectin represents a promising serological biomarker for the risk assessment of COVID-19 patients.

    Search related documents:
    Co phrase search for related documents
    • aat antitrypsin and acute respiratory syndrome: 1, 2, 3, 4
    • aat deficiency and acute respiratory syndrome: 1, 2
    • abdominal pain and acute ards respiratory distress syndrome: 1, 2, 3, 4
    • abdominal pain and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • abdominal pain nausea and acute ards respiratory distress syndrome: 1
    • abdominal pain nausea and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acid citrate dextrose and acute respiratory syndrome: 1
    • acute ards respiratory distress syndrome and additional prognostic factor: 1
    • acute ards respiratory distress syndrome and additional study: 1, 2, 3, 4, 5
    • acute ards respiratory distress syndrome and additional value: 1, 2, 3
    • acute respiratory syndrome and additional clinical trial: 1
    • acute respiratory syndrome and additional prognostic factor: 1
    • acute respiratory syndrome and additional study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and additional value: 1, 2, 3, 4, 5, 6, 7, 8